Open access
Open access
Powered by Google Translator Translator

Critical Care & Emergencies (all articles)

RCT supports the use of therapeutic heparin in moderately ill patients admitted to the hospital with Covid-19.

17 Oct, 2021 | 21:35h | UTC

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial – The BMJ

Commentary: High-dose of readily available blood thinner reduces risk of death for moderately ill COVID-19 patients – St. Michael’s Hospital

Related studies (some conflicting results)

RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Commentary on Twitter

 


Serious injury risk higher for horse riding than for football, motor racing, or skiing – “Chest most common site of injury, but head and neck injuries most lethal”.

17 Oct, 2021 | 21:08h | UTC

News release: Serious injury risk higher for horse riding than for football, motor racing, or skiing – BMJ

Original study: Hearing hoofbeats? Think head and neck trauma: a 10-year NTDB analysis of equestrian-related trauma in the USA – Trauma Surgery & Acute Care Open

Commentary: Horse Riding More Dangerous Than Skiis And Motorcycles, Injury Data Reveal – Science Alert

 


Review: Management of infectious emergencies for the inpatient dermatologist.

17 Oct, 2021 | 21:06h | UTC

Management of Infectious Emergencies for the Inpatient Dermatologist – Current Dermatology Reports (if this link is paywalled, try this one)

 


Review: Timing of antibiotic therapy in the ICU.

17 Oct, 2021 | 21:05h | UTC

Timing of antibiotic therapy in the ICU – Critical Care

 


Intracerebral hemorrhage: diagnosis, emergency management, and prognosis.

15 Oct, 2021 | 02:12h | UTC

Intracerebral Hemorrhage: Diagnosis, Emergency Management, and Prognosis – emDocs

 


Systematic Review: Ultrasound guidance for arterial (other than femoral) catheterization in adults may improve first attempt and overall success rates compared to palpation.

14 Oct, 2021 | 09:41h | UTC

Ultrasound guidance for arterial (other than femoral) catheterisation in adults – Cochrane Library

 


M-A: Frequency of Neurologic Manifestations in COVID-19 – up to one-third of patients (89% hospitalized) experienced at least one neurological manifestation.

13 Oct, 2021 | 01:40h | UTC

Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis – Neurology

 


Consensus Guidance: Hyperkalemia management in the emergency department.

13 Oct, 2021 | 01:34h | UTC

Hyperkalemia management in the emergency department: An expert panel consensus – Journal of the American College of Emergency Physicians Open

Related: Review: Clinical Management of Hyperkalemia. Classification and monitoring, when to reinitiate RAASi therapy, use oral K+-binding agents, and more

Podcast: Hyperkalemia, Diet, K+ Binders, Exercise

Hyperkalemia: Pathophysiology, Risk Factors and Consequence

Hyperkalemia: Pathophysiology, Risk Factors and Consequence (several articles)

 


RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19.

12 Oct, 2021 | 00:28h | UTC

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial – JAMA

Editorial: Antithrombotic Therapy for Outpatients With COVID-19: Implications for Clinical Practice and Future Research – JAMA

 

Commentary on Twitter

 


D-Dimer testing for the exclusion of pulmonary embolism has limited clinical utility among hospitalized patients with COVID-19 – most patients with or without pulmonary embolism have increased levels.

12 Oct, 2021 | 00:26h | UTC

D-Dimer Testing for the Exclusion of Pulmonary Embolism Among Hospitalized Patients With COVID-19 – JAMA Network Open

Commentary: D-Dimer Level Not Useful for Ruling Out PE in COVID-19 Patients – HealthDay

 


How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

12 Oct, 2021 | 00:18h | UTC

How antiviral pill molnupiravir shot ahead in the COVID drug hunt – Nature

Related:

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 


RCT: In patients with acute ischemic stroke and large vessel occlusion, thrombectomy with combined contact aspiration and stent retriever was not better than stent retriever alone.

12 Oct, 2021 | 00:04h | UTC

Effect of Thrombectomy With Combined Contact Aspiration and Stent Retriever vs Stent Retriever Alone on Revascularization in Patients With Acute Ischemic Stroke and Large Vessel Occlusion: The ASTER2 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentaries:

Little Benefit From Adding Aspiration to Thrombectomy for Stroke – Medscape (free registration required)

Combo Thrombectomy Approach No Better for Large Vessel Strokes – MedPage Today (free registration required)

 

Commentary on Twitter

 


Cluster RCT: An antimicrobial stewardship intervention safely reduced the use of broad-spectrum antibiotics among patients hospitalized with moderately severe community-acquired pneumonia.

11 Oct, 2021 | 23:55h | UTC

Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)

 


RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

10 Oct, 2021 | 21:53h | UTC

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial – JAMA Internal Medicine

Invited commentary: Anticoagulant Therapy in Patients Hospitalized With COVID-19 – JAMA Internal Medicine

Related studies (some conflicting results)

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Commentary on Twitter

 


WHO Guidance: Antigen-detection in the diagnosis of SARS-CoV-2 infection.

8 Oct, 2021 | 10:47h | UTC

Antigen-detection in the diagnosis of SARS-CoV-2 infection – World Health Organization

Related infographics:

Use of antigen detection rapid diagnostic testing – World Health Organization

Diagnostic testing for SARS-CoV-2 infection – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


Study shows an increased risk of Guillain-Barré Syndrome with the J&J vaccine; the estimated observed to expected rate ratio was 4.18 for the 42-day window.

8 Oct, 2021 | 10:40h | UTC

Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021 – JAMA

 

Commentary on Twitter

 


RCT: Immediate drainage did not improve outcomes compared to postponed intervention in patients with infected necrotizing pancreatitis.

7 Oct, 2021 | 10:35h | UTC

Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis – New England Journal of Medicine

 


What we know — and don’t know — about Merck’s new Covid-19 pill.

6 Oct, 2021 | 10:07h | UTC

What we know — and don’t know — about Merck’s new Covid-19 pill – STAT

Related:

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 


SILENCE Randomized Trial: In patients at the end of life, prophylactic subcutaneous scopolamine butylbromide reduces the occurrence of the death rattle (noisy breathing caused by mucus in the upper respiratory tract).

6 Oct, 2021 | 09:54h | UTC

Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of LifeThe SILENCE Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide – JAMA (free for a limited period)

Author interview: Scopolamine Butylbromide for Preventing End-of-Life Death Rattle – JAMA

 

Commentary on Twitter

 


RCT: An active strategy for diagnosing pulmonary embolism did not improve outcomes in patients hospitalized for COPD exacerbation.

6 Oct, 2021 | 09:52h | UTC

Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial – JAMA (free for a limited period)

 

Commentary on Twitter

 


RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

5 Oct, 2021 | 10:06h | UTC

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial – JAMA

Commentary: Convalescent plasma futile as treatment for critically ill COVID-19 patients, study finds – University of Pittsburgh

Related:

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 


Merck’s Covid-19 pill is great news but may not be a game-changer.

5 Oct, 2021 | 09:59h | UTC

Merck’s Covid-19 pill is great news but may not be a game-changer – CNN

 


Video | A Pill For COVID? A Doctor Explains Molnupiravir.

5 Oct, 2021 | 09:57h | UTC

A Pill For COVID? | A Doctor Explains Molnupiravir – ZDoggMD

 


AHA Scientific Statement: Diagnosis and management of patients with myocardial injury after noncardiac surgery.

5 Oct, 2021 | 09:01h | UTC

Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association – Circulation

News Release: 1 in 5 adults has high levels of heart enzymes after any surgery, monitoring advised – American Heart Association

Commentary: AHA: More Screening Needed to Catch Myocardial Injury After Noncardiac Surgery – TCTMD

 


Intra-abdominal hypertension and abdominal compartment syndrome in critically ill patients: A narrative review of past, present, and future steps.

5 Oct, 2021 | 08:52h | UTC

Intra-abdominal hypertension and abdominal compartment syndrome in critically ill patients: A narrative review of past, present, and future steps – Scandinavian Journal of Surgery

 


Stay Updated in Your Specialty

No spam, just news.